Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Cash from Investing Activities
Adaptimmune Therapeutics PLC
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Cash from Investing Activities
$176.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Investing Activities
-$127m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Investing Activities
-$11m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Investing Activities
-$2.9m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Investing Activities
-£5.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Cash from Investing Activities
-£21.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
See Also
What is Adaptimmune Therapeutics PLC's Cash from Investing Activities?
Cash from Investing Activities
176.5m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Cash from Investing Activities amounts to 176.5m USD.
What is Adaptimmune Therapeutics PLC's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
98%
Over the last year, the Cash from Investing Activities growth was 98%.